文献速递眼底病与葡萄膜炎

骨保护素是增殖性糖尿病视网膜病变中炎症和血管生成的新调节因子

Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

该研究检测了47例增殖性糖尿病视网膜病变(PDR)患者和28例非糖尿病患者的玻璃体样本、14例PDR患者的视网膜前膜、10例糖尿病患者和10例非糖尿病受试者的人视网膜以及大鼠视网膜和人视网膜微血管内皮细胞(HRMEC),发现PDR患者玻璃体中骨保护素(OPG)、血管内皮生长因子(VEGF)和单核细胞趋化蛋白-1(MCP-1/CCL2)表达显著增加且OPG与VEGF、MCP-1/CCL2水平呈显著正相关,OPG在HRMEC中由TNF-α和IL-1β诱导上调并促进细胞迁移、增强VEGF的血管生成效应,提示OPG参与PDR血管生成。

要点

  • PDR患者玻璃体中OPG、VEGF和MCP-1/CCL2表达较非糖尿病对照显著增加,且OPG与VEGF、MCP-1/CCL2水平呈显著正相关。
  • OPG在PDR视网膜前膜的血管内皮细胞和基质细胞中表达,糖尿病患者视网膜中OPG mRNA和蛋白显著增加。
  • TNF-α和IL-1β(而非VEGF、MCP-1/CCL2或凝血酶)诱导HRMEC中OPG上调,OPG促进HRMEC迁移并增强VEGF的血管生成效应。

核心结论

  • 这些结果提示OPG参与PDR血管生成。

研究设计与样本

  • 研究纳入47例PDR患者和28例非糖尿病患者的玻璃体样本、14例PDR患者的视网膜前膜、10例糖尿病患者和10例非糖尿病受试者的人视网膜、大鼠视网膜及HRMEC,采用酶联免疫吸附试验、免疫组织化学、免疫荧光、蛋白质印迹分析和RT-PCR检测,并进行体外和体内血管生成实验。

主要发现

  • PDR患者玻璃体样本与非糖尿病对照相比,OPG、VEGF和MCP-1/CCL2表达显著增加。
  • OPG水平与VEGF水平、MCP-1/CCL2水平之间呈显著正相关。
  • 视网膜前膜中OPG表达于血管内皮细胞和基质细胞;糖尿病患者视网膜中OPG mRNA和蛋白显著增加。
  • TNF-α和IL-1β而非VEGF、MCP-1/CCL2或凝血酶诱导HRMEC中OPG上调。
  • OPG诱导HRMEC中ERK1/2和Akt磷酸化并刺激其迁移,且在体内蛋白明胶栓实验中增强VEGF的血管生成效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Osteoprotegerin (OPG) is a novel regulator of endothelial cell function, angiogenesis, and vasculogenesis. We correlated expression levels of OPG with those of the angiogenic and inflammatory factors vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1/CCL2) in proliferative diabetic retinopathy (PDR). We also examined expression of OPG in retinas from diabetic rats and diabetic patients and measured production of OPG by human retinal microvascular endothelial cells (HRMEC) and investigated its angiogenic activity. METHODS: Vitreous samples from 47 PDR and 28 nondiabetic patients, epiretinal membranes from 14 patients with PDR, human retinas (10 from diabetic patients and 10 from nondiabetic subjects), and rat retinas and HRMEC were studied by using enzyme-linked immunosorbent assay, immunohistochemistry, immunofluorescence, Western blot analysis, and RT-PCR. In vitro and in vivo angiogenesis assays were performed. RESULTS: We showed a significant increase in the expression of OPG, VEGF, and MCP-1/CCL2 in a comparison between vitreous samples from PDR patients and those from nondiabetic controls. Significant positive correlations were found between levels of OPG and levels of VEGF and MCP-1/CCL2. In epiretinal membranes, OPG was expressed in vascular endothelial cells and stromal cells. Significant increases of OPG mRNA and protein were detected in the retinas from diabetic patients. The proinflammatory cytokines TNF-α and IL-1β, but not VEGF, MCP-1/CCL2 or thrombin, induced upregulation of OPG in HRMEC. Osteoprotegerin induced ERK1/2 and Akt phosphorylation in HRMEC and stimulated their migration. Osteoprotegerin potentiated the angiogenic effect of VEGF in the in vivo protein gelatin plug assay. CONCLUSIONS: These results suggest that OPG is involved in PDR angiogenesis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Abu El-Asrar AM, Struyf S, Mohammad G, et al. Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017. PMID: 28654984. doi:10.1167/iovs.16-20993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。